Malignant Pleural Effusion Clinical Trial
Official title:
Video Assisted Thoracoscopic Surgery (VATS) - Surgical Pleurodesis vs Tube Drainage in Management of Malignant Pleural Effusion (MPE)
Malignant Pleural Effusion (MPE) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. It carries a burden on our patients with dyspnea being the most common symptom in most of cases. Management of symptomatic malignant pleural effusion remains to be a point of debate. Data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. Options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. Surgical intervention with abrasion pleurodesis or pleurectomy using VATS approach has been used in many studies. Using indwelling pleural catheters (IPCs) has also proved comparable efficacy at many clinical trials. In this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 30, 2025 |
Est. primary completion date | March 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 90 Years |
Eligibility | Inclusion Criteria: - 1-patients with symptomatic malignant pleural effusion. 2- symptomatic patients with shortness of breath. 3-Lung can be fully expanded. Exclusion Criteria: 1. Patients with non symptomatic malignant pleural effusion 2. Pleural symphysis with no potentiality for re-expansion 3. Patients managed surgically through open thoracotomy. 4. Pleural effusion due to causes other than malignancy 5. Loculated malignant effusion judged by chest ultrasound 6. Trapped lung due to malignant pleural effusion assessed by multislice CT chest., 7. .Refusal to share the research project and not to sign the consent. |
Country | Name | City | State |
---|---|---|---|
Egypt | Assiut university heart hospital | Assiut |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total hospital stay | duration of hospital stay in days | 3 months postoperative | |
Primary | duration of airleak | duration in days | 3 months postoperative | |
Secondary | Status of performance | patient reported outcome through a pre-prepared questionnaire | 3 months | |
Secondary | mortality | Rate of mortality | '3 months | |
Secondary | Failure of management | time to re-collection | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00052338 -
Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT06421610 -
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
|
Phase 1 | |
Recruiting |
NCT04793607 -
Interventions for Malignant Pleural Effusions Impact on Fatigue
|
||
Recruiting |
NCT03987087 -
A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT02942043 -
Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT01997190 -
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT00564733 -
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT04131231 -
Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion
|
N/A | |
Completed |
NCT02674243 -
Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion
|
Phase 3 | |
Terminated |
NCT01004510 -
Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00528645 -
AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00313066 -
Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion
|
Phase 4 | |
Terminated |
NCT04236037 -
Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura
|
N/A | |
Completed |
NCT05372055 -
Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
|
||
Not yet recruiting |
NCT04914598 -
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
|
Phase 3 | |
Recruiting |
NCT04322136 -
AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion
|
N/A | |
Recruiting |
NCT03973957 -
Talc Outpatient Pleurodesis With Indwelling Catheter
|
N/A | |
Recruiting |
NCT05923515 -
A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
|
Phase 1 | |
Completed |
NCT02649894 -
Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter
|
N/A | |
Recruiting |
NCT03403855 -
Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients
|
N/A |